-
公开(公告)号：US20050070588A1
公开(公告)日：2005-03-31
申请号：US10932594
申请日：2004-09-01
Applicant: David Weinstein , Khehyong Ngu , Jeffrey Robl
Inventor： David Weinstein , Khehyong Ngu , Jeffrey Robl
IPC: C07D233/54 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/14 , C07D417/04 , C07D471/10 , C07D487/08 , C07D233/38 , A61K31/4172 , A61K31/4178
CPC classification number: C04B35/632 , C07D233/64 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/14 , C07D417/04 , C07D471/10 , C07D487/08
Abstract: The present invention provides imidazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.
Abstract translation: 本发明提供15-LO的咪唑基抑制剂，含有这种抑制剂的药物组合物和使用这些化合物和组合物治疗与15-LO级联相关的疾病的方法。
-
公开(公告)号：US07820814B2
公开(公告)日：2010-10-26
申请号：US12399429
申请日：2009-03-06
Applicant: Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
Inventor： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC: C07D487/04 , A61K31/53 , A61P35/00
CPC classification number: C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US20070299075A1
公开(公告)日：2007-12-27
申请号：US11832976
申请日：2007-08-02
Applicant: Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
Inventor： Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC: A61K31/4196 , A61P43/00 , C07D253/06
CPC classification number: C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐。式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其用作抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
14.发明申请Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods 审中-公开基于金刚烷基甘氨酸的二肽基肽酶IV抑制剂及方法公开(公告)号：US20050228021A1
公开(公告)日：2005-10-13
申请号：US11149414
申请日：2005-06-09
Applicant: Lawrence Hamann , Ashish Khanna , Mark Kirby , David Magnin , Ligaya Simpkins , James Sutton , Jeffrey Robl
Inventor： Lawrence Hamann , Ashish Khanna , Mark Kirby , David Magnin , Ligaya Simpkins , James Sutton , Jeffrey Robl
IPC: C07C255/46 , C07C255/47 , C07D207/16 , C07D209/52 , C07D277/04 , C07D295/185 , A61K31/445 , A61K31/275 , A61K31/401 , A61K31/403 , A61K31/426
CPC classification number: C07C255/46 , C07C255/47 , C07C2601/08 , C07C2602/18 , C07C2603/74 , C07D207/16 , C07D209/52 , C07D277/04 , C07D295/185
Abstract: Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
Abstract translation: 提供具有式（I）的化合物，其中：n为0,1或2; m为0,1或2; n + m的和小于等于2; 当Y是CH时，形成环丙基环的虚线键只能存在; X是H或CN; Y是CH，CH 2 CH 2，CHF，CF 2 O，O，S，SO或SO 2。 而A是金刚烷基。 还提供了使用这些化合物治疗糖尿病和相关疾病的方法，以及含有这些化合物的药物组合物。
-
公开(公告)号：US20080108649A1
公开(公告)日：2008-05-08
申请号：US11931282
申请日：2007-10-31
Applicant: Chong-Qing Sun , Lawrence Hamann , David Augeri , Yingzhi Bi , Jeffrey Robl , Yan-Ting Huang , Tammy Wang , Alexandra Holubec , Ligaya Simpkins , James Sutton , James Li
Inventor： Chong-Qing Sun , Lawrence Hamann , David Augeri , Yingzhi Bi , Jeffrey Robl , Yan-Ting Huang , Tammy Wang , Alexandra Holubec , Ligaya Simpkins , James Sutton , James Li
IPC: A61K31/4545 , A61K31/4164 , A61K31/47 , A61P21/00 , C07D217/00 , C07D235/00 , C07D471/02
CPC classification number: C07D487/04 , C07D471/04
Abstract: There are provided compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention. Other embodiments are also disclosed.
Abstract translation: 提供根据式I的化合物，其中取代基如本文所述。 进一步提供的是使用这些化合物来治疗核激素受体相关病症的方法，例如年龄相关疾病，例如肌肉减少症。 还提供了含有这些化合物的药物组合物和制备本发明的一些化合物的方法。 还公开了其他实施例。
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20050038020A1
公开(公告)日：2005-02-17
申请号：US10899641
申请日：2004-07-27
Applicant: Lawrence Hamann , Ashish Khanna , Mark Kirby , David Magnin , Ligaya Simpkins , James Sutton , Jeffrey Robl
Inventor： Lawrence Hamann , Ashish Khanna , Mark Kirby , David Magnin , Ligaya Simpkins , James Sutton , Jeffrey Robl
IPC: C07C255/46 , C07C255/47 , C07D207/16 , C07D209/52 , C07D277/04 , C07D295/185 , C07D279/12 , A61K31/445 , A61K31/54 , C07D211/06 , C07D265/30
CPC classification number: C07C255/46 , C07C255/47 , C07C2601/08 , C07C2602/18 , C07C2603/74 , C07D207/16 , C07D209/52 , C07D277/04 , C07D295/185
Abstract: Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
Abstract translation: 提供具有式（I）的化合物，其中：n为0,1或2; m为0,1或2; n + m的和小于等于2; 当Y是CH时，形成环丙基环的虚线键只能存在; X是H或CN; Y是CH，CH 2，CHF，CF 2，O，S，SO或SO 2; 而A是金刚烷基。 还提供了使用这些化合物治疗糖尿病和相关疾病的方法，以及含有这些化合物的药物组合物。
-
公开(公告)号：US07772267B2
公开(公告)日：2010-08-10
申请号：US11931282
申请日：2007-10-31
Applicant: Chong-qing Sun , Lawrence Hamann , David Augeri , Yingzhi Bi , Jeffrey Robl , Yan-Ting Huang , Tammy Wang , Alexandra Holubec , Ligaya Simpkins , James C. Sutton , James J. Li
Inventor： Chong-qing Sun , Lawrence Hamann , David Augeri , Yingzhi Bi , Jeffrey Robl , Yan-Ting Huang , Tammy Wang , Alexandra Holubec , Ligaya Simpkins , James C. Sutton , James J. Li
IPC: A61K31/415 , C07D235/02
CPC classification number: C07D487/04 , C07D471/04
Abstract: There are provided compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention. Other embodiments are also disclosed.
Abstract translation: 提供根据式I的化合物，其中取代基如本文所述。 进一步提供的是使用这些化合物来治疗核激素受体相关病症的方法，例如年龄相关疾病，例如肌肉减少症。 还提供了含有这些化合物的药物组合物和制备本发明的一些化合物的方法。 还公开了其他实施例。
-
公开(公告)号：US07405234B2
公开(公告)日：2008-07-29
申请号：US10780415
申请日：2004-02-17
Applicant: Chong-Qing Sun , Lawrence Hamann , David Augeri , Yingzhi Bi , Jeffrey Robl , Yan-Ting Huang , Tammy Wang , Alexandra Holubec , Ligaya Simpkins , James C. Sutton , James J. Li
Inventor： Chong-Qing Sun , Lawrence Hamann , David Augeri , Yingzhi Bi , Jeffrey Robl , Yan-Ting Huang , Tammy Wang , Alexandra Holubec , Ligaya Simpkins , James C. Sutton , James J. Li
IPC: A61K31/415 , C07D235/02
CPC classification number: C07D487/04 , C07D471/04
Abstract: The invention provides compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.
Abstract translation: 本发明提供式I化合物，其中取代基如本文所述。 进一步提供的是使用这些化合物来治疗核激素受体相关病症的方法，例如年龄相关疾病，例如肌肉减少症。 还提供了含有这些化合物的药物组合物和制备本发明的一些化合物的方法。
-
19.发明申请TRIAZINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS 有权TRIAZINE 11-BETA HYDROOSTEROID DEHYDROGENASE TYPE 1 INHIBITORS公开(公告)号：US20070207985A1
公开(公告)日：2007-09-06
申请号：US11679898
申请日：2007-02-28
Applicant: Jun Li , Jeffrey Robl , Lawrence Kennedy
Inventor： Jun Li , Jeffrey Robl , Lawrence Kennedy
IPC: A61K31/675 , A61K31/55 , A61K31/541 , A61K31/5377 , A61K31/53 , C07D403/02 , C07D413/02 , C07D417/02
CPC classification number: C07D253/10 , C07D253/07
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.
Abstract translation: 提供了新的化合物，其为11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。 这些新化合物具有以下结构：其立体异构体或前药或其药学上可接受的盐，其中R 1，R 2和R 3 3定义在本文中 。
-
公开(公告)号：US07265113B2
公开(公告)日：2007-09-04
申请号：US11035248
申请日：2005-01-13
Applicant: Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
Inventor： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC: C07D487/04 , A61K31/53 , A61P35/00
CPC classification number: C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.023 seconds)
